SYMJEPI (epinephrine) Injection logo

FOR TYPE 1 ALLERGIC REACTIONSSYMJEPI (epinephrine) INJECTION IS THE CHOICE THAT FITS1,2*

The SYMJEPI Injection has a compact design that provides the same active ingredient as contained in the most widely used epinephrine auto-injectors (EAIs).1-3*

*SYMJEPI is not an EAI.1

SYMJEPI (epinephrine) Injection 0.3 mg pre-filled single-dose syringes packaging

SYMJEPI package not pictured at actual size. The image is intended to illustrate the difference in package size between SYMJEPI and 2 currently available EAIs.2

SYMJEPI has the lowest Wholesale Acquisition Cost (WAC) vs. currently available EAIs. Furthermore, SYMJEPI has a WAC that is approximately 17% below the WAC of the most widely used EAI. 2

Based on data on file as of 12/18/2018.2

How to use SYMJEPI3
1
READY

When ready to use SYMJEPI, pull cap off to expose needle.
To ensure no accidental epinephrine leakage, do not touch the plunger until the needle is fully inserted.

2
STEADY

Holding by the finger grips, slowly insert the needle into the thigh. SYMJEPI can be injected through clothing if necessary.

3
GO

After needle is in the thigh, push the plunger all the way down until it clicks. Hold for 2 seconds. Remove syringe and massage the area for 10 seconds.

The correct dose has been injected if the plunger has been pushed all the way down and the solution window is at least partially blocked.

4
PROTECT

Once the injection has been administered, using one hand with your fingers behind the needle, slide the safety guard up until it clicks to cover the needle.

IMPORTANT NOTE: SYMJEPI should ONLY be injected into the middle of the outer thigh. Do not inject into the vein, buttock, fingers, toes, hands, or feet.1

Exclamation point
SYMJEPI features a safety guard to keep users protected3
See how to use SYMJEPI in this short video

A simple way to recall these steps when using SYMJEPI is to remember “Ready, Steady, Go, Protect.”

Preparation free and space-saving storage1,2

Each SYMJEPI ready-to-use syringe delivers a 0.3-mg dose of epinephrine for the emergency treatment of Type 1 allergic reactions, including anaphylaxis, to1:

  • Diagnostic testing substances (eg, radiocontrast media)

  • Foods or drugs

  • Allergen immunotherapy

  • Stinging and biting insects

SYMJEPI can be used to treat idiopathic anaphylaxis or exercise-induced anaphylaxis as well.1

Scale Icon
SYMJEPI 0.3 mg is indicated for patients weighing approximately 66 lb (30 kg) or more.1
  • APPROVED SEPTEMBER 2018:
    SYMJEPI 0.15 mg, for patients weighing 33 lb to 66 lb (15 kg to 30 kg)1

SYMJEPI single-dose syringe 2-pack
SYMJEPI comes in a convenient 2-pack, with each single-dose syringe featuring1:
  • A thinner needle than that in the most widely used EAI2,4‡

  • A safety guard for careful handling3

SYMJEPI is not an EAI.1

Thermometer icon: 68 degrees-77 degrees fahrenheit
The epinephrine in SYMJEPI is light sensitive and should be stored between 68°F and 77°F (20°C and 25°C).1

SYMJEPI is the space-saving and cost-effective option for the treatment of allergic emergencies.1,2

How to order
Phone icon with Sandoz Key Account Manager on screen
For more information and instructions on the use of SYMJEPI, call 1-800-230-3935.
Indication

SYMJEPI is indicated in the emergency treatment of allergic reactions (Type 1) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis.

Important Safety Information
CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS
  • In conjunction with use, seek immediate medical or hospital care.

  • Do not inject intravenously, into buttock, or into digits, hands or feet.

  • To minimize the risk of injection-related injury, instruct caregivers to hold the child's leg firmly in place and limit movement prior to and during injection when administering to young children.

  • Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop signs or symptoms of infection at the epinephrine injection site.

  • The presence of a sulfite in this product should not deter use.

  • Administer with caution in patients with heart disease; may aggravate angina pectoris or produce ventricular arrhythmias.

ADVERSE REACTIONS

Adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

DRUG INTERACTIONS
  • Cardiac glycosides, anti-arrhythmics or diuretics: observe for development of cardiac arrhythmias.

  • Tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines: potentiate effects of epinephrine.

  • Beta-adrenergic blocking drugs: antagonize cardiostimulating and bronchodilating effects of epinephrine.

  • Alpha-adrenergic blocking drugs: antagonize vasoconstricting and hypertensive effects of epinephrine.

  • Ergot alkaloids: may reverse the pressor effects of epinephrine.

USE IN SPECIFIC POPULATIONS

Elderly patients may be at greater risk of developing adverse reactions.

Please see full Prescribing Information for SYMJEPI.

To report SUSPECTED ADVERSE REACTIONS, contact Adamis Pharmaceuticals Corporation at 1-800-230-3935 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

References: 1. Symjepi [prescribing information]. San Diego, CA: Adamis Pharmaceuticals Corporation; 2018. 2. Data on file. Sandoz Inc. 3. Symjepi [instructions for use]. San Diego, CA: Adamis Pharmaceuticals Corporation; 2018. 4. Stecher D, Bulloch B, Sales J, Schaefer C, Keahey L. Epinephrine auto-injectors: is needle length adequate for delivery of epinephrine intramuscularly? Pediatrics. 2009;124(1):65-70.

Sandoz A Novartis Division Logo
SYMJEPI (epinephrine) Injection logo

SYMJEPI is a trademark of Adamis Pharmaceuticals Corporation.

© 2019 Sandoz Inc., a Novartis Division.
100 College Road West, Princeton, NJ 08540.
All Rights Reserved. S-SMJ-1377497  07/2019

Indication

SYMJEPI is indicated in the emergency treatment of allergic reactions (Type 1) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis.

Important Safety Information
CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS
  • In conjunction with use, seek immediate medical or hospital care.

  • Do not inject intravenously, into buttock, or into digits, hands or feet.

  • To minimize the risk of injection-related injury, instruct caregivers to hold the child's leg firmly in place and limit movement prior to and during injection when administering to young children.

  • Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop signs or symptoms of infection at the epinephrine injection site.

  • The presence of a sulfite in this product should not deter use.

  • Administer with caution in patients with heart disease; may aggravate angina pectoris or produce ventricular arrhythmias.

ADVERSE REACTIONS

Adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

DRUG INTERACTIONS
  • Cardiac glycosides, anti-arrhythmics or diuretics: observe for development of cardiac arrhythmias.

  • Tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines: potentiate effects of epinephrine.

  • Beta-adrenergic blocking drugs: antagonize cardiostimulating and bronchodilating effects of epinephrine.

  • Alpha-adrenergic blocking drugs: antagonize vasoconstricting and hypertensive effects of epinephrine.

  • Ergot alkaloids: may reverse the pressor effects of epinephrine.

USE IN SPECIFIC POPULATIONS

Elderly patients may be at greater risk of developing adverse reactions.

Please see full Prescribing Information for SYMJEPI.

To report SUSPECTED ADVERSE REACTIONS, contact Adamis Pharmaceuticals Corporation at 1-800-230-3935 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

clear
Indication

SYMJEPI is indicated in the emergency treatment of allergic reactions (Type 1) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis.

Important Safety Information
CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS
  • In conjunction with use, seek immediate medical or hospital care.

  • Do not inject intravenously, into buttock, or into digits, hands or feet.

  • To minimize the risk of injection-related injury, instruct caregivers to hold the child's leg firmly in place and limit movement prior to and during injection when administering to young children.

  • Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop signs or symptoms of infection at the epinephrine injection site.

  • The presence of a sulfite in this product should not deter use.

  • Administer with caution in patients with heart disease; may aggravate angina pectoris or produce ventricular arrhythmias.

ADVERSE REACTIONS

Adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

DRUG INTERACTIONS
  • Cardiac glycosides, anti-arrhythmics or diuretics: observe for development of cardiac arrhythmias.

  • Tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines: potentiate effects of epinephrine.

  • Beta-adrenergic blocking drugs: antagonize cardiostimulating and bronchodilating effects of epinephrine.

  • Alpha-adrenergic blocking drugs: antagonize vasoconstricting and hypertensive effects of epinephrine.

  • Ergot alkaloids: may reverse the pressor effects of epinephrine.

USE IN SPECIFIC POPULATIONS

Elderly patients may be at greater risk of developing adverse reactions.

Please see full Prescribing Information for SYMJEPI.

To report SUSPECTED ADVERSE REACTIONS, contact Adamis Pharmaceuticals Corporation at 1-800-230-3935 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.